News | October 23, 2023
RPG Life Sciences posts Q2 FY24 PAT at Rs. 25.86 Cr
RPG Life Sciences has reported total income of Rs. 155.41 crores during the period ended September 30, 2023
RPG Life Sciences has reported total income of Rs. 155.41 crores during the period ended September 30, 2023
Investment is additive to KKR’s existing health care growth strategy
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
New Board of Directors and management team at Suven Pharma also appointed
Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction
The company has received the Establishment Inspection Report (EIR) from the USFDA for the Pre-Approval Inspection (PAI) at a manufacturing site situated at Savli, Vadodara, Gujarat, with Zero 483 observations
Parecoxib Sodium is the first parenteral selective COX-2 inhibitor available for clinical use in pain management
Patients Treated with ARIKAYCE plus macrolide-based background regimen had meaningfully larger improvements in QOL-B respiratory score
Subscribe To Our Newsletter & Stay Updated
